Suppression of mitochondrial respiration with auraptene inhibits the progression of renal cell carcinoma: Involvement of HIF-1a degradation

Oncotarget

Volumn 6, Issue 35, 2015, Pages 38127-38138

  Jang, Yunseon ^a   Han, Jeongsu ^a   Kim, Soo Jeong ^a   Kim, Jungim ^a   Lee, Min Joung ^a   Jeong, Soyeon ^a   Ryu, Min Jeong ^a   Seo, Kang Sik ^a   Choi, Song Yi ^a   Shong, Minho ^a   Lim, Kyu ^a   Heo, Jun Young ^a   Kweon, Gi Ryang ^a  

^a Chungnam National University   (South Korea)

Author keywords

Auraptene; eIF2a; HIF 1a; Mitochondrial respiration; Renal cell carcinoma

Indexed keywords

6 PHOSPHOFRUCTOKINASE; AURAPTENE; GLUCOSE TRANSPORTER 1; HEXOKINASE; HEXOKINASE 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE A; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; ANGIOGENESIS INHIBITOR; COUMARIN DERIVATIVE; HIF1A PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CARCINOGENESIS; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENERGY METABOLISM; GENE MUTATION; GENETIC TRANSCRIPTION; GLYCOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MALE; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; PROTEIN CONTENT; PROTEIN DEGRADATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; TRANSLATION INITIATION; ANGIOGENESIS; ANIMAL; BIOSYNTHESIS; CARCINOMA, RENAL CELL; CELL MOTION; CELL RESPIRATION; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HELA CELL LINE; KIDNEY NEOPLASMS; METABOLISM; MITOCHONDRION; MUTATION; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; TIME FACTOR; TUMOR INVASION; TUMOR VOLUME; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, RENAL CELL; CELL MOVEMENT; CELL RESPIRATION; COUMARINS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENERGY METABOLISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; HELA CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; MALE; MICE, NUDE; MITOCHONDRIA; MUTATION; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEOLYSIS; RNA INTERFERENCE; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84947804558     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5511     Document Type: Article

References (43)

1. Benhaim R, Oussoultzoglou E, Saeedi Y, Mouracade P, Bachellier P, Lang H. Pancreatic metastasis from clear cell renal cell carcinoma: outcome of an aggressive approach. Urology. 2015; 85:135-140.
2. Hamada S, Ito K, Kuroda K, Sato A, Asakuma J, Horiguchi A, Seguchi K, Asano T. Clinical characteristics and prognosis of patients with renal cell carcinoma and liver metastasis. Mol Clin Oncol. 2015; 3:63-68.
3. Erdem S, Yegen G, Telci D, Yildiz I, Tefik T, Issever H, Kilicaslan I, Sanli O. The increased transglutaminase 2 expression levels during initial tumorigenesis predict increased risk of metastasis and decreased disease-free and cancer-specific survivals in renal cell carcinoma. World J Urol. 2014.
4. Sotgia F, Whitaker-Menezes D, Martinez-Outschoorn UE, Flomenberg N, Birbe RC, Witkiewicz AK, Howell A, Philp NJ, Pestell RG, Lisanti MP. Mitochondrial metabolism in cancer metastasis: visualizing tumor cell mitochondria and the "reverse Warburg effect" in positive lymph node tissue. Cell Cycle. 2012; 11:1445-1454.
5. Lu J, Tan M, Cai Q. The Warburg effect in tumor progression: Mitochondrial oxidative metabolism as an anti-metastasis mechanism. Cancer Lett. 2015; 356:156-164.
6. Kamarajugadda S, Stemboroski L, Cai Q, Simpson NE, Nayak S, Tan M, Lu J. Glucose oxidation modulates anoikis and tumor metastasis. Mol Cell Biol. 2012; 32:1893-1907.
7. LeBleu VS, O'Connell JT, Gonzalez Herrera KN, Wikman H, Pantel K, Haigis MC, de Carvalho FM, Damascena A, Domingos Chinen LT, Rocha RM, Asara JM, Kalluri R. PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol. 2014; 16:992-1003. 1001-1015.
8. Palorini R, Simonetto T, Cirulli C, Chiaradonna F. Mitochondrial complex I inhibitors and forced oxidative phosphorylation synergize in inducing cancer cell death. Int J Cell Biol. 2013; 2013:243876.
9. Chen V, Staub RE, Fong S, Tagliaferri M, Cohen I, Shtivelman E. Bezielle selectively targets mitochondria of cancer cells to inhibit glycolysis and OXPHOS. PLoS One. 2012; 7:e30300.
10. Momose I, Ohba S, Tatsuda D, Kawada M, Masuda T, Tsujiuchi G, Yamori T, Esumi H, Ikeda D. Mitochondrial inhibitors show preferential cytotoxicity to human pancreatic cancer PANC-1 cells under glucose-deprived conditions. Biochem Biophys Res Commun. 2010; 392:460-466.
11. Li J, Mahdi F, Du L, Jekabsons MB, Zhou YD, Nagle DG. Semisynthetic studies identify mitochondria poisons from botanical dietary supplements-geranyloxycoumarins from Aegle marmelos. Bioorg Med Chem. 2013; 21:1795-1803.
12. Tanaka T, Kohno H, Murakami M, Kagami S, El-Bayoumy K. Suppressing effects of dietary supplementation of the organoselenium 1,4-phenylenebis(methylene)selenocyanate and the Citrus antioxidant auraptene on lung metastasis of melanoma cells in mice. Cancer Res. 2000; 60:3713-3716.
13. Krishnan P, Yan KJ, Windler D, Tubbs J, Grand R, Li BD, Aldaz CM, McLarty J, Kleiner-Hancock HE. Citrus auraptene suppresses cyclin D1 and significantly delays N-methyl nitrosourea induced mammary carcinogenesis in female Sprague-Dawley rats. BMC Cancer. 2009; 9:259.
14. Tanaka T, Kawabata K, Kakumoto M, Matsunaga K, Mori H, Murakami A, Kuki W, Takahashi Y, Yonei H, Satoh K, Hara A, Maeda M, Ota T, Odashima S, Koshimizu K, Ohigashi H. Chemoprevention of 4-nitroquinoline 1-oxide-induced oral carcinogenesis by citrus auraptene in rats. Carcinogenesis. 1998; 19:425-431.
15. Jun DY, Kim JS, Park HS, Han CR, Fang Z, Woo MH, Rhee IK, Kim YH. Apoptogenic activity of auraptene of Zanthoxylum schinifolium toward human acute leukemia Jurkat T cells is associated with ER stress-mediated caspase-8 activation that stimulates mitochondria-dependent or-independent caspase cascade. Carcinogenesis. 2007; 28:1303-1313.
16. Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, Giaccia AJ, Kurban G, Pause A, Frydman J, Zurita AJ, Rini BI, Sharma P, Atkins MB, Walker CL, Rathmell WK. State of the science: an update on renal cell carcinoma. Mol Cancer Res. 2012; 10:859-880.
17. Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland M, de Bruine AP. VHL and HIF signalling in renal cell carcinogenesis. J Pathol. 2010; 221:125-138.
18. Bausch B, Jilg C, Glasker S, Vortmeyer A, Lutzen N, Anton A, Eng C, Neumann HP. Renal cancer in von Hippel-Lindau disease and related syndromes. Nat Rev Nephrol. 2013; 9:529-538.
19. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer. 2008; 8:705-713.
20. Bardos JI, Ashcroft M. Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays. 2004; 26:262-269.
21. Stubbs M, Griffiths JR. The altered metabolism of tumors: HIF-1 and its role in the Warburg effect. Adv Enzyme Regul. 2010; 50:44-55.
22. Cui SY, Huang JY, Chen YT, Song HZ, Huang GC, De W, Wang R, Chen LB. The role of Aurora A in hypoxia-inducible factor 1alpha-promoting malignant phenotypes of hepatocelluar carcinoma. Cell Cycle. 2013; 12:2849-2866.
23. Jang M, Kim SS, Lee J. Cancer cell metabolism: implications for therapeutic targets. Exp Mol Med. 2013; 45:e45.
24. Carew JS, Esquivel JA 2nd, Espitia CM, Schultes CM, Mulbaier M, Lewis JD, Janssen B, Giles FJ, Nawrocki ST. ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma. PLoS One. 2012; 7:e31120.
25. Wang Z, Dabrosin C, Yin X, Fuster MM, Arreola A, Rathmell WK, Generali D, Nagaraju GP, El-Rayes B, Ribatti D, Chen YC, Honoki K, Fujii H, Georgakilas AG, Nowsheen S, Amedei A, et al. Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol. 2015.
26. Powis G, Kirkpatrick L. Hypoxia inducible factor-1alpha as a cancer drug target. Mol Cancer Ther. 2004; 3:647-654.
27. Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest. 2013; 123:3664-3671.
28. Moore LE, Nickerson ML, Brennan P, Toro JR, Jaeger E, Rinsky J, Han SS, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Schmidt LS, et al. Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors. PLoS Genet. 2011; 7:e1002312.
29. Liu YV, Semenza GL. RACK1 vs. HSP90: competition for HIF-1 alpha degradation vs. stabilization. Cell Cycle. 2007; 6:656-659.
30. Minet E, Mottet D, Michel G, Roland I, Raes M, Remacle J, Michiels C. Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. FEBS Lett. 1999; 460:251-256.
31. Zhu K, Chan W, Heymach J, Wilkinson M, McConkey DJ. Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression. Cancer Res. 2009; 69:1836-1843.
32. Twardowski P, Figlin RA. Bevacizumab plus interferon alpha in patients with metastatic renal cell carcinoma. Nat Clin Pract Oncol. 2008; 5:436-437.
33. Roulin D, Waselle L, Dormond-Meuwly A, Dufour M, Demartines N, Dormond O. Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. Mol Cancer. 2011; 10:90.
34. Garcia JA, Hutson TE, Elson P, Cowey CL, Gilligan T, Nemec C, Dreicer R, Bukowski RM, Rini BI. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer. 2010; 116:5383-5390.
35. Hutson TE, Bukowski RM, Cowey CL, Figlin R, Escudier B, Sternberg CN. Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol. 2011; 77:48-62.
36. Zhao L, Zhao X, Zhao K, Wei P, Fang Y, Zhang F, Zhang B, Ogata K, Mori A, Wei T. The alpha-tocopherol derivative ESeroS-GS induces cell death and inhibits cell motility of breast cancer cells through the regulation of energy metabolism. Eur J Pharmacol. 2014; 745: 98-107.
37. McLachlan A, Kekre N, McNulty J, Pandey S. Pancratistatin: a natural anti-cancer compound that targets mitochondria specifically in cancer cells to induce apoptosis. Apoptosis. 2005; 10:619-630.
38. Okuyama S, Yamamoto K, Mori H, Toyoda N, Yoshimura M, Amakura Y, Yoshida T, Sugawara K, Sudo M, Nakajima M, Furukawa Y. Auraptene in the Peels of Citrus kawachiensis (Kawachi Bankan) Ameliorates Lipopolysaccharide-Induced Inflammation in the Mouse Brain. Evid Based Complement Alternat Med. 2014; 2014:408503.
39. Wang L, Williamson SR, Wang M, Davidson DD, Zhang S, Baldridge LA, Du X, Cheng L. Molecular subtyping of metastatic renal cell carcinoma: implications for targeted therapy. Mol Cancer. 2014; 13:39.
40. Koh MY, Spivak-Kroizman T, Venturini S, Welsh S, Williams RR, Kirkpatrick DL, Powis G. Molecular mechanisms for the activity of PX-48, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol Cancer Ther. 2008; 7:90-100.
41. Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res. 2004; 64:1475-1482.
42. Wu B, Teng H, Yang G, Wu L, Wang R. Hydrogen sulfide inhibits the translational expression of hypoxia-inducible factor-1alpha. Br J Pharmacol. 2012; 167:1492-1505.
43. Cowey CL, Rathmell WK. Using Molecular Biology to Develop Drugs for Renal Cell Carcinoma. Expert Opin Drug Discov. 2008; 3:311-327.